Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewiMAC2 is an inhibitor of mitochondrial apoptosis-induced channel (MAC) (IC50 = 28 nM). Reduces STS-induced apoptosis in FL5.12 cells by over 50%. Inhibits release of cytochrome c by Bid-induced Bax activation (IC50 = 0.68 μM).
分子量 | 542.11 |
公式 | C19H20Br2FN3.2HCl |
储存 | Desiccate at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 335166-00-2 |
PubChem ID | 90488878 |
InChI Key | JWCVUOLQOHIRML-UHFFFAOYSA-N |
Smiles | BrC(C=C3)=CC1=C3N(CC(F)CN4CCNCC4)C2=C1C=C(Br)C=C2.Cl.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Bombrun et al (2003) 3,6-dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome c release via Bax channel modulation. J.Med.Chem. 46 4365 PMID: 14521400
Peixoto et al (2009) MAC inhibitors suppress mitochondrial apoptosis. Biochem.J. 423 381 PMID: 19691447
关键词: iMAC2, iMAC2 supplier, MAC, inhibitor, mitochondrial, apoptosis-induced, channel, inhibitors, inhibits, reduces, apoptosis, bax, Other, Apoptosis, Bcl-2, Family, 3794, Tocris Bioscience
目前没有该产品的评论。 Be the first to review iMAC2 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.